Asian Fund for Cancer Research shared a post on LinkedIn:
”Traditional cancer clinical trials are slow and costly, and many patients cannot afford to wait.
AFCR is advancing the “PIONEER Oncology” – a bold new platform offering a faster, smarter, and more affordable approach to early-phase cancer clinical trials. Through in-human microtrials, parallel screening, biomarker-guided, and AI-powered analysis, we can significantly shorten trial timelines and reduce costs, so patients don’t have to wait as long for new treatment options.
Cancer research can’t wait. Your support can give patients a greater chance at life.
More about the Asian Fund for Cancer Research.